Abstract: The association of inhaled corticosteroids (ICS) and pneumonia in patients with chronic obstructive pulmonary disease (COPD) is still controversial.
INTRODUCTION
C ombination therapy with inhaled corticosteroids (ICS)/ long-acting b 2 agonists (LABA) is a cornerstone in the treatment of chronic obstructive pulmonary disease (COPD), which is characterized by both airway and systemic inflammation. 1 Two recent large clinical trials have demonstrated that ICS plus LABA can improve lung function and health status, and possibly reduce the frequency of acute exacerbation (AE) and mortality. 2, 3 Long-term ICS therapy, however, is reported to increase the risk of pneumonia among COPD patients. [4] [5] [6] [7] A recent metaanalysis reports an odds ratio (OR) of 1.78 (95% confidence interval [CI]: 1.50-2.12) and 1.62 (95% CI: 1.00-2.62) for fluticasone and budesonide, respectively. 4 Another metaanalysis using individual patient data from 7 clinical trials has a different conclusion and that budesonide is not associated with increased risk of pneumonia. 8 The discrepancy may be due to differences in study designs and definitions of pneumonia among individual clinical trial. Moreover, pneumonia is simply an adverse event rather than the primary endpoint in these trials. Thus, a large cohort study with specific focus may be more suitable than currently available meta-analyses to understand the impact of ICS on the risk of pneumonia among COPD patients.
Recent cohort studies using health insurance claims data have shown an association between ICS use and increased risk of pneumonia. 9, 10 However, due to the built-in shortness of the symptoms and lung function results, none of these studies can control the confounding effect of COPD severity. This may have serious implications since COPD patients who require ICS therapy are usually those with severely impaired lung function and an increased risk of respiratory tract infection. 11 Other potential bias that has not yet been addressed in previous studies is that in real-world clinical practice, the severity of COPD and the dose of each drug may vary with time. For that, a time-dependent approach is a more suitable statistical method.
The National Health Insurance (NHI) of Taiwan is a mandatory universal health insurance program offering comprehensive medical care coverage to nearly 100% of the residents in Taiwan since 1996. 12 The Longitudinal Health Insurance Database (LHID) 2005, a subset database of the NHI program, contains the entire original claims data from 1996 to 2007 of 1,000,000 beneficiaries randomly sampled from the year 2005 Registry for Beneficiaries. This study used surrogate variables to control COPD severity and applied timedependent Cox proportional hazards analysis to identify the risk factors of pneumonia among COPD patients identified in the LHID 2005, with special emphasis on the impact of ICS. The incidence rates of pneumonia before and during ICS use, and after discontinuation of ICS in the same patients were compared.
MATERIALS AND METHODS
The Institutional Review Board of the Taipei Medical University approved the study and waived the need for informed consent due to the retrospective design using an encrypted database (TMU REC: 201503024).
The study was divided into 2 parts (Figure 1 ). In the first part, COPD cases with history of AE were selected from the LHID 2005 to study the effect of its treatments and co-morbidities on the risk of developing pneumonia (COPD cohort). All selected cases were followed-up until pneumonia developed, December 31, 2007, or until the patient was lost to follow-up.
In the second part of the study, patients in the COPD cohort who continuously used ICS for more than 360 days were identified (ICS cohort), in which continuous use was defined as no interruption for more than 30 days. The incidence rates of pneumonia before and during ICS use, as well as after discontinuation of ICS, were compared.
Selection Criteria of COPD Patients With AE
In this study, COPD was defined as more than 2 out-patient or in-patient records <365 days apart with the compatible diagnoses between 1996 and 2007, and prescription of more than 2 COPD-specific medications or 1 COPD-specific medication plus at least 1 airway medication(s) in 3 months. 13 The compatible diagnoses of COPD included the International Classification of Diseases, 9th revision, clinical modification (ICD-9-CM) codes 491, 492, 496, and A-code A325. Corticosteroids (inhaled, oral, or parenteral), beta-agonists (long-acting or short-acting; inhaled, oral, or parenteral), anti-cholinergics (ipratropium or tiotropium), aminophylline, and theophylline were considered COPD-specific medications.
Among patients who fulfilled the selection criteria of COPD, those with 2 episodes of AE within 1 year or 1 episode of AE requiring hospitalization were identified, with the first AE date defined as the enrollment date. In this study, AE was defined as emergency department visits or admissions with the ICD-9-CM codes 491, 492, 496, and A-code A325, plus prescription of systemic corticosteroids. The index date was noted as 365 days after the enrollment date. The baseline frequency of AE was calculated during the 1-year period from the enrollment to the index date.
Definition of Pneumonia
The diagnostic criteria of pneumonia consisted of a compatible diagnosis (ICD-9-CM codes 480-486 and A-codes A321) in the out-patient or in-patient discharge records, and prescriptions of pneumonia-specific antibiotics and chest radiography. Pneumonia-specific antibiotics included systemic beta-lactams and/or beta-lactamase inhibitors, fluoroquinolones, macrolides, and carbapenems. The presence of pneumonia events between the enrollment and index dates were also recorded.
Co-Morbidities
Underlying co-morbidities present before the index date were recorded, including malignancy, diabetes mellitus, endstage renal disease (ESRD), liver cirrhosis, autoimmune diseases, pneumoconiosis, and acquired immunodeficiency syndrome. Organ transplantation and low-income status were identified according to a previous publication. 14 
Statistical Analysis
The prescription duration of individual drugs were converted from claims data according to the defined daily doses (DDDs) 15 and grouped according to their pharmacologic categories. Inhaled and systemic corticosteroids were converted to an equivalent dose of budesonide 800 mg and prednisolone in milligrams, respectively. 16 In the first part of the study, variables potentially associated with the development of pneumonia within 180 days after the index date in the COPD cohort were analyzed using a timedependent Cox proportional hazards model. The presence of baseline pneumonia event, baseline frequency of AE, and a time-dependent variable for the frequency of AE after the index date were used as surrogates for COPD severity in the statistical model. 17 Other variables included age, sex, co-morbidities, and the time-dependent variables for the prescribed medications. All time-dependent variables were determined as the total prescribed dose of each specific class of medication and the total number of AE from 120 to 30 days prior to the end of each period. Significance for entry and stay were set at 0.15. Statistical significance was set at a 2-sided P < 0.05.
In order to ensure patients in a relatively stable condition either before or after treatment modification, and to avoid the potential confounding effects lasting from previous status, a 6-month period being 3 months prior to ICS use, 3 months before and 3 months after ICS discontinuation were selected to calculate the incidence rate of pneumonia in the ICS cohort in the second part of the study and compared using paired t test. All analyses were performed using SAS (SAS Institute Inc., Cary, NC, USA). Table 1 and their mean age (69.6 AE 10.6 years) was older than that of the nonpneumonia cases (67.2 AE 11.4 years). The pneumonia cases also had more male predominance (68.1% vs 63.7%) and had a higher prevalence of diabetes mellitus (24.9% vs 21.4%), but less prevalence of liver cirrhosis (0% vs 0.2%). Patients who developed pneumonia during the study period also had higher frequency of AE (3.3 AE 4.9 vs 2.4 AE 3.5 event/person-year) and were more likely to have pneumonia (22.1% vs 12.2%) in baseline condition. Other baseline characteristics listed in Table 1 were not significantly different between the 2 groups. In addition, the use of oral corticosteroids (per gram of prednisolone) (HR: 1.21; 95% CI: 1.18-1.24) and aminophylline (each increment of 30 DDDs) (HR: 1.11; 95% CI: 1.08-1.13) from prior 120 to 30 days were also associated with increased risk of pneumonia. The number of AE (HR: 1.09; 95% CI: 1.05-1.12) from prior 120 to 30 days and presence of baseline pneumonia event (HR: 1.87; 95% CI: 1.70-2.06) were associated with increased risk of pneumonia.
Factors Predicting the Development of Pneumonia

The ICS Cohort and the Impact of ICS Use on Pneumonia Events
There were 842 COPD patients in the ICS cohort. Their clinical characteristics were summarized in Table 3 . Their mean age was 65.9 AE 12.4 years and there was 74.3% male predominance. Like the COPD cohort, the presence of diabetes mellitus (19.0%) and malignancy (3.7%) were the most common co-morbidities. The baseline frequency of AE was 1.7 AE 4.0 event/person-year and 150 (17.8%) had pneumonia at baseline.
In the ICS cohort, 37 (4.4%), 64 (7.6%), and 46 (5.5%) patients developed pneumonia in the selected 6-month period before ICS use, during ICS use, and after ICS discontinuation, respectively. The rate of pneumonia events during ICS use (0.21 event/person-year) was significantly higher than that before ICS use (0.10 events/person-years) (P ¼ 0.001, by paired t test) and not significantly different from that after ICS discontinuation (0. 
DISCUSSION
By analyzing longitudinal data form a nationwide cohort, this study has 2 important findings. First, using time-dependent analysis and controlling for COPD severity, the use of ICS has an independent and dose-dependent effect of increasing the risk of pneumonia. Second, while the incidence rate of AE continues to decrease, the incidence rate of pneumonia increases during ICS use and has a decreasing trend after ICS discontinuation.
Both airway and systemic inflammation characterize COPD. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend that a fixed combination of ICS/LABA should be considered for group C or D patients, who are highly symptomatic or have high risk of complications. 1 Although helpful in reducing inflammation, ICS has many potential short-and long-term side effects.
1 A higher risk of pneumonia while using ICS has been observed in several clinical trials, [18] [19] [20] including the TOwards a Revolution Yet, some studies demonstrate the opposite.
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Similarly, not all meta-analyses have the same conclusions on whether ICS use increase the risk of pneumonia. 4, 8 The recently published meta-analysis of 43 randomized controlled trials indicated that budesonide and fluticasone, delivered alone or in combination with a LABA, are associated with increased risk of pneumonia (budesonide: OR 1.62, 95% CI 1.00-2.62; fluticasone: OR 1.78, 95% CI 1.50-2.12). 4 One explanation for the discrepancy is that the incidence rate of pneumonia in these clinical trials has been calculated from adverse event report, in which not every single pneumonia event is confirmed by chest radiography and microbiologic data. Chest radiography was done in 72% and 58% of the reported pneumonia events in the TORCH and INSPIRE studies, respectively. 2, 3 Furthermore, the study design and treatment protocols were heterogeneous among these clinical trials.
Despite the lack of randomization, retrospective cohort studies may enroll much larger patient numbers than clinical trials. Patients with underlying co-morbidities are also more likely to develop certain complications but are always excluded in clinical trials. Thus, retrospective cohort studies, but not clinical trials, are more likely to represent the real-world situation. Several observational studies conducted to investigate the impact of ICS on the risk of pneumonia in COPD patients show an estimated relative risk of 1.11 to 3.26.
7,9,10,24 -26 Some even demonstrate a positive dose-response relationship between ICS and risk of pneumonia. 7, 9, 10, 24, 25 However, these studies have 2 major limitations. First, without judicious control of the severity of COPD, the impact of ICS on the risk of pneumonia may be overestimated since COPD patients who require ICS therapy are usually those with severely impaired lung function, which in turn is associated with increased risk of respiratory tract infection. 11 Second, the dose of ICS is averaged in a certain period and arbitrarily categorized into 2 or 3 levels, in contrast to the real-world situation where it almost always varies with time.
This is the first study investigating the impact of ICS on the risk of pneumonia by applying time-dependent variables to represent the dynamic characteristics of COPD severity and medications. The presence of baseline pneumonia event, and baseline and recent frequency of AE were used as surrogates for controlling COPD severity. 17 Because this study only includes COPD patients with more than 2 AEs or any AE requiring hospitalization within the 1-year period between enrollment and index date, the enrolled subjects are likely to represent those who really need ICS therapy. 1 The results provide evidence showing that ICS can increase the risk of pneumonia among COPD patients. In time-dependent multivariate Cox regression analysis, recent ICS use is independently associated with an increased risk for developing pneumonia. This is also the first study providing longitudinal data on the incidence rate of pneumonia and AE before, during, and after ICS use. While the incidence rate of AE decreases gradually, the incidence rate of pneumonia increases significantly during ICS use. The findings are consistent with current knowledge that ICS plus LABA can prevent AE of COPD while rendering patients more susceptible to pneumonia. 2, 3 The finding that baseline pneumonia event, recent frequency of AE, and oral aminophylline use are independently associated with increased risk of pneumonia is not surprising. All of the 3 variables may correlate with the severity of COPD, which in turns correlates with the risk of pneumonia. 11, 27 All of the other independent risk factors of pneumonia, including aging, co-morbid diabetes mellitus or malignancy, low income, and oral corticosteroid use, are well associated with immunosuppression, [28] [29] [30] [31] [32] therefore increasing the possibility of developing pneumonia. Past evidence also supports the finding that men have a higher incidence of pneumonia than women, probably because of smoking and other lifestyle factors. 33 There are some limitations in this study. Due to the built-in shortage of claims data and retrospective design, the diagnoses of COPD and its severity, as well as pneumonia, are not confirmed. Though baseline frequency of AE and pneumonia event, and a time-dependent variable for the AE frequency were used as surrogate indicators in this study, they may not correlate 100% with COPD severity. Second, data on many possible confounding factors like nutritional status are not available. However, this study reports real-world findings and the results can therefore be applied to the majority of COPD patients.
In conclusion, using a nationwide cohort in Taiwan, this study demonstrates the association between ICS use and pneumonia in COPD patients. Hence, ICS should be used judiciously in indicated COPD patients.
